Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis

Review (6 trials;n=4061) found addition of daratumumab to backbone multiple myeloma (MM) regimens linked to significantly improved progression-free survival among patients with newly diagnosed high risk MM (HRMM) or relapsed or refractory HRMM (HR, 0.67;95% CI, 0.47-0.95;p =0.02)

JAMA Oncology